CXCL13 and neoplasm: Although the prevalence of CD8_C8_CXCL13 cells within NPC tumours is relatively low (scRNA-seq cohort: 0-9.89%; Multiplex IHC cohort: 0.5-11%; Supplementary Fig. 13h), their proportion was notably higher in early stage NPC tumours compared to those at advanced stages (Supplementary Fig. 13i).